Clinical Trial Update: Intravenous Iloprost in Subjects With Symptomatic Raynaud's Phenomenon Secondary to Systemic Sclerosis (Phase 2) [Phase 2]

View source ↗

Summary

This Phase 2 trial evaluated intravenous iloprost in subjects with Raynaud's phenomenon secondary to systemic sclerosis; results have been posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Raynaud Phenomenon
• Systemic Sclerosis

Drugs mentioned

• Ventavis (iloprost)

Snippet

Sponsor: Civi Biopharma, Inc. | Conditions: Raynaud Phenomenon Secondary to Systemic Sclerosis | Phase 2 | Status: COMPLETED | Results posted: 2025-05-25